Lipids & metabolic liver disease
Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD
Authors' conclusion
This study identified plasma proteins associated with MALOs in individuals with MASLD. Incorporation of a proteomics-derived risk score into the clinical model significantly improved predictive performance and was associated with greater liver disease activity
Study context
- Population
- Participants with MASLD from the UK Biobank
- Participants
- 14,166 participants
- Outcome
- Incident major adverse liver outcomes:
- MALOs: cirrhosis
- Hepatocellular carcinoma
- Follow-up
- Median 13.4 years
Methodological detailsUK Biobank, elastic net-penalised Cox regression with five-fold cross-validation
- UK Biobank
- Elastic net-penalised Cox regression with five-fold cross-validation
Main finding
As reported in the abstract
C-index
0.880
95% CI 0.847, 0.910
C-index increment
0.072
95% CI 0.041, 0.102
Proteins associated with major adverse liver outcomes (MALOs) (803 positively, 31 inversely; FDR-adjusted p-value < 0.01)
834
Observational data: associations, not effects.
Further findings
Incident MALOs · median follow-up 13.4 years
- Participants developing MALOs
- 151 (1.1%)
Top proteins associated with MALOs
- Top five positively associated: CDHR2, CEACAM1, FCAMR, LTBP2, GGT1; inversely: TTR, APOM, KITLG, C1orf56, PROC
Liver disease activity (MRI cT1) per SD increase in protein risk score (ProRS)
- β
- 7.50 (95% CI: 1.91, 13.10)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →